The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Early findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in R/R AML and HR-MDS
Shaun Fleming, MBBS, FRACP, FRCPA, Alfred Hospital, Melbourne, Australia, comments on the early safety and efficacy findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS). Dr Fleming notes that while early-phase data is limited, he hopes that this therapy will have fewer toxicities and enhanced efficacy as it targets a subset of T-cells. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
LAVA-1266 compound is very interesting as a novel T-cell engaging targeting CD123 which is a very good target in myeloid malignancies as it’s commonly expressed in acute myeloid leukemia and myelodysplastic syndrome. This is early phase data that we have currently it’s too difficult with such low doses and small numbers of patients to really comment about efficacy but I think what the encouraging part that we see is the deliverability of the therapy...
LAVA-1266 compound is very interesting as a novel T-cell engaging targeting CD123 which is a very good target in myeloid malignancies as it’s commonly expressed in acute myeloid leukemia and myelodysplastic syndrome. This is early phase data that we have currently it’s too difficult with such low doses and small numbers of patients to really comment about efficacy but I think what the encouraging part that we see is the deliverability of the therapy. I think immunotherapies have been a real challenge in acute myeloid leukemia, unlike in acute lymphoblastic leukemia where we’ve had real success stories and drugs getting to market. We haven’t yet really seen that in the AML space and this drug by taking a slightly different approach and targeting a subset of the T-cells rather than broadly engaging T-cells is hope that it can mitigate some of the toxicity profile and also enhance efficacy. And so this study is continuing and we continue to actively recruit patients in Australia and other countries, and hopefully we’ll have more data on efficacy in coming meetings.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
